FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated meaningful results' for people showing early symptoms of the disease

Federal health authorities on Tuesday gave approval to an experimental new drug that has shown to delay the onset of Alzheimer's disease in trials.

Donanemab, manufactured by Eli Lilly, is the second medication that has won the blessing of the Food and Drug Administration (FDA) to treat patients showing early symptoms of the disease, most prominently cognitive impairment.